OBJECTIVE: To identify the time point of the greatest degree of improvement in daily living activities, pain and depression in patients with osteoarthritis (OA) of the knee during 6 months of treatment with NSAIDs, in order to define compliance and drop-out rate.METHODS: 107 patients were recruited into a multicentre, prospective, randomized, controlled trial comparing two treatments, piroxicam-beta-cyclodextrin (PBCD) and slow release diclofenac (DCL).RESULTS: The greatest improvement in quality of life occurred in both groups after 3 months, with a slight further gain observed by the end of treatment. The Stanford Health Assessment Questionnaire score improved (p < 0.05 vs baseline) at 3 and 6 months with PBCD and at 6 months with DCL. The Arthritis Impact Measurement Scale score improved (p < 0.05 vs baseline) after 6 months in both groups. Significant (p < 0.05 vs baseline) improvement in other psychological and pain scores were recorded in both groups after 3 and 6 months. Compliance with treatment at 3 months was 73% for PBCD and 72% for DCL, and was 60% in both groups at 6 months.CONCLUSIONS: The results of this study indicate that the optimal length of time for an NSAID trial in OA patients is 3 months, when assessment of daily living activities is considered as the main outcome criterion.
Anno di pubblicazione: | 1998 |
Titolo: | Quality of life assessment during six months of NSAID treatment [Gonarthrosis and Quality of Life (GOAL) Study] |
Autore/i: | LA MONTAGNA G; TIRRI G; CACACE E; PERPIGNANO G; COVELLI M; PIPITONE V; D'AGOSTINO P; MAGARO M; FERRACCIOLI G; M. MASCIA; MANZINI E; MINARI C; BARRECA C; MARCOLONGO R; PARESCE E; COLOMBO B |
Autore/i UNIMORE: | |
Rivista: | |
Volume: | 16(1) |
Pagina iniziale: | 49 |
Pagina finale: | 54 |
Codice identificativo ISI: | WOS:000072462100009 |
Codice identificativo Scopus: | 2-s2.0-0031892112 |
Tipologia | Articolo su rivista |
File in questo prodotto:

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris